MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by MUELLER, R. A.
Right arrow Articles by AXELROD, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by MUELLER, R. A.
Right arrow Articles by AXELROD, J.

Molecular Pharmacology, Vol 5, 463-469, Copyright © 1969 by the American Society for Pharmacology and Experimental Therapeutics

Inhibition of Trans-synaptically Increased Tyrosine Hydroxylase Activity by Cycloheximide and Actinomycin D

ROBERT A. MUELLER 1, HANS THOENEN 1, and JULIUS AXELROD 1

1 Laboratory of Clinical Science, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland 20014

Reserpine produces a neurally mediated increase in tyrosine hydroxylase activity in the adrenal medullae and sympathetic ganglia of the rat. This increase in enzyme activity can be prevented by the administration of actinomycin D or cycloheximide. These results suggest that the synthesis of tyrosine hydroxylase is regulated either by changes in the release or turnover of catecholamines, or by the direct effect of a neurotransmitter. Reserpine increases the incorporation of 3H-leucine into hepatic and adrenal protein, and this incorporation is inhibited by a dose of cycloheximide that prevents the reserpine-initiated increase in tyrosine hydroxylase activity.

Submitted on April 9, 1969




This article has been cited by other articles:


Home page
 EndocrinologyHome page
B. Liu and L. A. Arbogast
Phosphorylation State of Tyrosine Hydroxylase in the Stalk-Median Eminence Is Decreased by Progesterone in Cycling Female Rats
Endocrinology, April 1, 2008; 149(4): 1462 - 1469.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
K. N. Furuya, J. V. Thottassery, E. G. Schuetz, M. Sharif, and J. D. Schuetz
Bromocriptine Transcriptionally Activates the Multidrug Resistance Gene (pgp2/mdr1b) by a Novel Pathway
J. Biol. Chem., April 25, 1997; 272(17): 11518 - 11525.
[Abstract] [Full Text] [PDF]

Home page
 ScienceHome page
I. Black, J. Adler, C. Dreyfus, W. Friedman, E. LaGamma, and A. Roach
Biochemistry of information storage in the nervous system
Science, June 5, 1987; 236(4806): 1263 - 1268.
[Abstract] [PDF]

Home page
 ScienceHome page
O. Viveros, C. Lee, M. Abou-Donia, J. Nixon, and C. Nichol
Biopterin cofactor biosynthesis: independent regulation of GTP cyclohydrolase in adrenal medulla and cortex
Science, July 17, 1981; 213(4505): 349 - 350.
[Abstract] [PDF]

Home page
 ScienceHome page
P Lerner, P Nose, E. Gordon, and W Lovenberg
Haloperidol: effect of long-term treatment on rat striatal dopamine synthesis and turnover
Science, July 8, 1977; 197(4299): 181 - 183.
[Abstract] [PDF]

Home page
 ScienceHome page
J. Axelrod
Noradrenaline: Fate and Control of Its Biosynthesis
Science, August 13, 1971; 173(3997): 598 - 606.
[PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1969 by the American Society for Pharmacology and Experimental Therapeutics